Skip to main content
Top
Published in: Diagnostic Pathology 1/2012

Open Access 01-12-2012 | Short report

Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco

Authors: Hinde El Fatemi, Sanae Chahbouni, Sofia Jayi, Kaoutar Moumna, My Abdelilah Melhouf, Abdelaziz Bannani, Omar Mesbahi, Afaf Amarti

Published in: Diagnostic Pathology | Issue 1/2012

Login to get access

Abstract

Background

Breast cancer may be classified into luminal A, luminal B, HER2+/ER-, basal-like and normal-like subtypes based on gene expression profiling or immunohistochemical (IHC) characteristics. The aim of our study is to show the molecular profile characteristic of breast cancer in the North African population of Morocco. This work showed preliminary results and correlations with clinicopathological and histological parameters. Three hundred and ninety primary breast carcinomas tumor tissues were immunostained for ER, PR, HER2, CK5/6, CK8/18 and Ki67 using paraffin tissue.

Methods

We reviewed 390 cases of breast cancer diagnosed on January 2008 to December 2011 at the Department of pathology, Hassan II teaching hospital, Fez, Morocco. Age, size tumor, metastatic profile, node involvement profile, histological type and immunohistochemical profile were studied.

Results

The average age was 46 years; our patients were diagnosed late with a high average tumor size. Luminal B subtype was more prevalent (41.8%), followed by luminal A (30.5%), basal-like (13, 6%), Her2-overexpressing (9, 2%), and unclassified subtype (4.9%).

Conclusion

This study showed that molecular classification and biological profile may be different according to geographical distribution, to encourage further studies to know the genomic profile of tumors and the environment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Perou CM, Sorlie T, Eisen MB, et al.: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed Perou CM, Sorlie T, Eisen MB, et al.: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed
2.
go back to reference Sorlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.PubMedCentralCrossRefPubMed Sorlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.PubMedCentralCrossRefPubMed
3.
go back to reference Sorlie T: Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004, 40: 2667-26675. 10.1016/j.ejca.2004.08.021.CrossRefPubMed Sorlie T: Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004, 40: 2667-26675. 10.1016/j.ejca.2004.08.021.CrossRefPubMed
4.
go back to reference Aleix P, Parker JS, Olga K, Cheng F, Chad L, Herschkowitz JI, Xiaping H, Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12: R68-10.1186/bcr2635.CrossRef Aleix P, Parker JS, Olga K, Cheng F, Chad L, Herschkowitz JI, Xiaping H, Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12: R68-10.1186/bcr2635.CrossRef
5.
go back to reference Bhargava R, Striebel J, Beriwal S, et al.: Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009, 2: 444-455.PubMedCentralPubMed Bhargava R, Striebel J, Beriwal S, et al.: Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009, 2: 444-455.PubMedCentralPubMed
6.
go back to reference Tang P, Wang J, Bourne P: Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?. Hum Pathol. 2008, 39: 506-513. 10.1016/j.humpath.2007.09.005.CrossRefPubMed Tang P, Wang J, Bourne P: Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?. Hum Pathol. 2008, 39: 506-513. 10.1016/j.humpath.2007.09.005.CrossRefPubMed
7.
go back to reference Pathology and genetics of tumours of the breast and female genital organs, world health organization classification of tumours. Edited by: Tavassoli F, Devilee P. 2003, Lyon: IARC Press Pathology and genetics of tumours of the breast and female genital organs, world health organization classification of tumours. Edited by: Tavassoli F, Devilee P. 2003, Lyon: IARC Press
8.
go back to reference Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology. 1991, 19 (5): 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology. 1991, 19 (5): 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed
10.
go back to reference Wolff AC, Elizabeth M, Hammond H, et al.: Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. American Society of Clinical Oncology/College of American Pathologists. J Clin Oncol. 2007, 25: 118-145.CrossRefPubMed Wolff AC, Elizabeth M, Hammond H, et al.: Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. American Society of Clinical Oncology/College of American Pathologists. J Clin Oncol. 2007, 25: 118-145.CrossRefPubMed
11.
go back to reference Prat A, Ellis MJ, Perou CM: Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol. 2011, 9 (1): 48-57. 10.1038/nrclinonc.2011.178.PubMedCentralCrossRefPubMed Prat A, Ellis MJ, Perou CM: Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol. 2011, 9 (1): 48-57. 10.1038/nrclinonc.2011.178.PubMedCentralCrossRefPubMed
12.
go back to reference Arvydas L, Aida L, Valerijus O, Darius D, Sonata J, Juozas L: Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol. 2012, 7: 27-10.1186/1746-1596-7-27.CrossRef Arvydas L, Aida L, Valerijus O, Darius D, Sonata J, Juozas L: Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol. 2012, 7: 27-10.1186/1746-1596-7-27.CrossRef
13.
go back to reference Ross JS, Fletcher JA, Bloom KJ, et al.: Targeted therapy in breast cancer. Mol Cell Proteomics. 2004, 3: 379-398. 10.1074/mcp.R400001-MCP200.CrossRefPubMed Ross JS, Fletcher JA, Bloom KJ, et al.: Targeted therapy in breast cancer. Mol Cell Proteomics. 2004, 3: 379-398. 10.1074/mcp.R400001-MCP200.CrossRefPubMed
14.
go back to reference Junichi K, Takoya M, Takanori I, et al.: The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races [abstract]. Breast. 2007, 16 (Suppl 2): S72-S77. Junichi K, Takoya M, Takanori I, et al.: The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races [abstract]. Breast. 2007, 16 (Suppl 2): S72-S77.
15.
go back to reference Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, De Vita F, Diadema MR, Orditura M, Colantuoni G, et al.: Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer. 2006, 94: 1604-1609.PubMedCentralPubMed Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, De Vita F, Diadema MR, Orditura M, Colantuoni G, et al.: Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer. 2006, 94: 1604-1609.PubMedCentralPubMed
16.
go back to reference Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V, Gonzalez S, Sauleda S, Marimon I, Tabernero JM, et al.: Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol. 2005, 23: 5323-5333. 10.1200/JCO.2005.08.326.CrossRefPubMed Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V, Gonzalez S, Sauleda S, Marimon I, Tabernero JM, et al.: Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol. 2005, 23: 5323-5333. 10.1200/JCO.2005.08.326.CrossRefPubMed
17.
go back to reference Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y: Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res. 2002, 8: 3454-3460.PubMed Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y: Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res. 2002, 8: 3454-3460.PubMed
18.
go back to reference Tsuda H, Morita D, Kimura M, Shinto E, Ohtsuka Y, Matsubara O, Inazawa J, Tamaki K, Mochizuki H, Tamai S, Hiraide H: Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci. 2005, 96: 48-53. 10.1111/j.1349-7006.2005.00009.x.CrossRefPubMed Tsuda H, Morita D, Kimura M, Shinto E, Ohtsuka Y, Matsubara O, Inazawa J, Tamaki K, Mochizuki H, Tamai S, Hiraide H: Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci. 2005, 96: 48-53. 10.1111/j.1349-7006.2005.00009.x.CrossRefPubMed
19.
go back to reference Walker RA, Dearing SJ: Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat. 1999, 53: 167-176. 10.1023/A:1006194700667.CrossRefPubMed Walker RA, Dearing SJ: Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat. 1999, 53: 167-176. 10.1023/A:1006194700667.CrossRefPubMed
20.
go back to reference Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005, 352: 786-792. 10.1056/NEJMoa044238.CrossRefPubMed Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005, 352: 786-792. 10.1056/NEJMoa044238.CrossRefPubMed
21.
go back to reference Kristensen VN: Divide and conquer: the genetic basis of molecular sub classification of breast cancer. EMBO Mol Med. 2011, 3: 183-185. 10.1002/emmm.201100128.PubMedCentralCrossRefPubMed Kristensen VN: Divide and conquer: the genetic basis of molecular sub classification of breast cancer. EMBO Mol Med. 2011, 3: 183-185. 10.1002/emmm.201100128.PubMedCentralCrossRefPubMed
22.
go back to reference Gomes DS, Débora B, Porto SS, Helenice G: Lobular neoplasia: frequency and association with other breast lesions. Diagn Pathol. 2011, 6: 74-10.1186/1746-1596-6-74. 9 August 2011PubMedCentralCrossRefPubMed Gomes DS, Débora B, Porto SS, Helenice G: Lobular neoplasia: frequency and association with other breast lesions. Diagn Pathol. 2011, 6: 74-10.1186/1746-1596-6-74. 9 August 2011PubMedCentralCrossRefPubMed
23.
go back to reference Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO: High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007, 31: 417-426. 10.1097/01.pas.0000213368.41251.b9.CrossRefPubMed Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO: High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007, 31: 417-426. 10.1097/01.pas.0000213368.41251.b9.CrossRefPubMed
24.
go back to reference Bratthauer GL, Tavassoli FA: Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clinical implications. Virchows Arch. 2002, 440: 134-138. 10.1007/s00428-001-0541-5.CrossRefPubMed Bratthauer GL, Tavassoli FA: Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clinical implications. Virchows Arch. 2002, 440: 134-138. 10.1007/s00428-001-0541-5.CrossRefPubMed
25.
go back to reference Peng XH, Karna P, O'Regan RM, Liu X, Naithani R, Moriarty RM, Wood WC, Lee HY, Yang L: Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol. 2007, 71 (1): 101-111.CrossRefPubMed Peng XH, Karna P, O'Regan RM, Liu X, Naithani R, Moriarty RM, Wood WC, Lee HY, Yang L: Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol. 2007, 71 (1): 101-111.CrossRefPubMed
26.
go back to reference Bockbrader KM, Tan M, Sun Y: A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene. 2005, 24 (49): 7381-7388. 10.1038/sj.onc.1208888.CrossRefPubMed Bockbrader KM, Tan M, Sun Y: A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene. 2005, 24 (49): 7381-7388. 10.1038/sj.onc.1208888.CrossRefPubMed
27.
go back to reference Yutao Z, Jianhua Z, Yun T, Feng L, Hongyuan Z, Bofang P, Chifeng Z, Rong F: X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma. Diagn Pathol. 2011, 6: 49-10.1186/1746-1596-6-49.CrossRef Yutao Z, Jianhua Z, Yun T, Feng L, Hongyuan Z, Bofang P, Chifeng Z, Rong F: X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma. Diagn Pathol. 2011, 6: 49-10.1186/1746-1596-6-49.CrossRef
28.
go back to reference Matter K, Balda MS: Signaling to and from tight junctions. Nat Rev Mol Cell Biol. 2003, 4: 225-236.CrossRefPubMed Matter K, Balda MS: Signaling to and from tight junctions. Nat Rev Mol Cell Biol. 2003, 4: 225-236.CrossRefPubMed
29.
go back to reference Tsukita S, Furuse M: Occludin and claudins in tight-junction strands: leading or supporting players?. Trends Cell Biol. 1999, 9: 268-273. 10.1016/S0962-8924(99)01578-0.CrossRefPubMed Tsukita S, Furuse M: Occludin and claudins in tight-junction strands: leading or supporting players?. Trends Cell Biol. 1999, 9: 268-273. 10.1016/S0962-8924(99)01578-0.CrossRefPubMed
30.
go back to reference Tsukita S, Furuse M, Itoh M: Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001, 2: 285-293. 10.1038/35067088.CrossRefPubMed Tsukita S, Furuse M, Itoh M: Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001, 2: 285-293. 10.1038/35067088.CrossRefPubMed
31.
go back to reference Santos PB, Zanetti JS, Silva AR, Beltrão EIC: Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagnostic Pathology. 2012, 7: 104-10.1186/1746-1596-7-104.PubMedCentralCrossRefPubMed Santos PB, Zanetti JS, Silva AR, Beltrão EIC: Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagnostic Pathology. 2012, 7: 104-10.1186/1746-1596-7-104.PubMedCentralCrossRefPubMed
32.
go back to reference MariadelasMercedes N, Fernando P, Florencia P, Néstor L, Hugo K, Silvana N, Alejandro G, Alejandra A, Boris E, Valeria D, Miembro de la Carrera de Investigador del Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET): Immunohistochemical characterization of neoplastic cells of breast origin. Diagn Pathol. 2012, 7: 73-10.1186/1746-1596-7-73.CrossRef MariadelasMercedes N, Fernando P, Florencia P, Néstor L, Hugo K, Silvana N, Alejandro G, Alejandra A, Boris E, Valeria D, Miembro de la Carrera de Investigador del Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET): Immunohistochemical characterization of neoplastic cells of breast origin. Diagn Pathol. 2012, 7: 73-10.1186/1746-1596-7-73.CrossRef
Metadata
Title
Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco
Authors
Hinde El Fatemi
Sanae Chahbouni
Sofia Jayi
Kaoutar Moumna
My Abdelilah Melhouf
Abdelaziz Bannani
Omar Mesbahi
Afaf Amarti
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2012
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-7-170

Other articles of this Issue 1/2012

Diagnostic Pathology 1/2012 Go to the issue